CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 17 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-18 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise | +57,763 | $2.06 | $119K | 59,553 |
| 2021-05-18 | Horn Kinney CHIEF BUSINESS OFFICER | Sale | −49,142 | $24.03 | $1.2M | 10,411 |
| 2021-05-18 | Horn Kinney CHIEF BUSINESS OFFICER | Sale | −8,621 | $24.81 | $214K | 1,790 |
| 2021-05-18 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −57,763 | 194,297 | ||
| 2021-04-05 | Larson Yi Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2021-04-05 | Larson Yi Director | Grant or award · Stock Option (Right to Buy) | +3,773 | 3,773 | ||
| 2021-03-31 | BVF PARTNERS L P/IL Director | Other acquisition | +99,556 | 99,556 | ||
| 2021-03-15 | Horn Kinney Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-03-15 | Bohen Sean President and CEO | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2020-11-23 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +1,273,420 | 1,273,420 | ||
| 2020-11-23 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +451,986 | 1,725,406 | ||
| 2020-11-23 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series B Preferred Stock | −1,273,420 | 0 | ||
| 2020-11-23 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series C Preferred Stock | −451,986 | 0 | ||
| 2020-11-23 | Cormorant Asset Management, LP Former 10% Owner | Conversion | +2,845,544 | 2,845,544 | ||
| 2020-11-23 | Cormorant Asset Management, LP Former 10% Owner | Purchase | +425,000 | $19.00 | $8.1M | 3,270,544 |
| 2020-11-23 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series B Convertible Preferred Stock | −2,122,367 | 0 | ||
| 2020-11-23 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series C Convertible Preferred Stock | −723,177 | 0 | ||
| 2020-11-23 | Graham G. Walmsley Director | Conversion | +1,400,761 | 1,400,761 | ||
| 2020-11-23 | Graham G. Walmsley Director | Conversion | +1,183,114 | 1,183,114 | ||
| 2020-11-23 | Graham G. Walmsley Director | Purchase | +1,160,000 | $19.00 | $22.0M | 1,160,000 |
Page 19 of 21 · 402 trades